

Client: Example Client ABC123 123 Test Drive Salt Lake City, UT 84108 UNITED STATES

Physician: Doctor, Example

Carbamazepine, Total

ARUP test code 0090260

Carb

Patient: Patient, Example

DOB	3/1/2004
Gender:	Male
Patient Identifiers:	01234567890ABCD, 012345
Visit Number (FIN):	01234567890ABCD
Collection Date:	00/00/0000 00:00

bamazepine	<pre><2.0 ug/mL L (Ref Interval: 4.0-12.0) Performed By: ARUP Laboratories at University Hospital 50 North Medical Drive Salt Lake City, UT 84132 Laboratory Director: Lauren N. Pearson, DO, MPH</pre>		
	INTERPRETIVE INFORMATION: Carbamazepine Therapeutic range for Carbamazepine 4.0-12.0 ug/mL Toxic level Greater than 15.0 ug/mL		
	The therapeutic range is based on serum pre-dose (trough) draw at steady-state concentration. Carbamazepine is also subject to drug-drug interactions due to displacement of protein binding and extensive metabolism. Cross-reactivity with metabolites may account for differences in carbamazepine among analytical methods.		
	A rare adverse drug reaction to carbamazepine therapy includes Stevens-Johnson syndrome or toxic epidermal necrolysis. Patients of Asian ancestry with the presence of the HLA-B*15:02 have an increased risk for this carbamazepine-induced life-threatening reaction. Pharmacogenetic testing for HLA-B*15:02 prior to treatment is recommended for patients at risk for carbamazepine hypersensitivity. This information has been included in the FDA-approved label for carbamazepine (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event= overview.process&varApplNo=016608) and guideline from the Clinical Pharmacogenetics Implementation Consortium (https://www.pharmgkb.org/guidelines). [HLA-B*15:02 Genotyping, Carbamazepine Hypersensitivity, ARUP test code 2012049.] A combination of therapeutic drug monitoring with HLA-B*15:02 pharmacogenetics genotyping may benefit patients who are at increased risk for developing carbamazepine-induced adverse events due to rare genotypes other than HLA-B*15:02 variant allele.		

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com 500 Chipeta Way, Sati Lake City, UT 84108-1221 Jonathan R. Genzen, MD, PhD, Laboratory Director



VERIFIED/REPORTED DATES				
Procedure	Accession	Collected	Received	Verified/Reported
Carbamazepine	21-268-102598	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

END OF CHART

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com 500 Chipeta Way, Salt Lake City, UT 84108-1221 Jonathan R. Genzen, MD, PhD, Laboratory Director Patient: Patient, Example ARUP Accession: 21-268-102598 Patient Identifiers: 01234567890ABCD, 012345 Visit Number (FIN): 01234567890ABCD Page 2 of 2 | Printed: 11/16/2022 7:50:20 AM 4848